Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

Part of paid clinical trials in San Antonio, Texas.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT06609343
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • End Stage Renal Disease
  • Fatigue

Eligibility Criteria

Sex
ALL
Age
25 Years - 74 Years
Healthy Volunteers
Not accepted

Interventions

  • Bupropion Hydrochloride 150 MG — DRUG
    Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks

Study Details

Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients. In this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.

Key Dates

Start date
Jun 1, 2026
Status verified
Mar 2026
Primary completion
Nov 30, 2026
Completion
Jan 30, 2027

Study Design

Enrollment
16 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Hemodialysis Group
    Fixed dose bupropion hydrochloride 150 mg extended-release tablets will be administered orally thrice a week during routine dialysis sessions for consecutive 8 weeks.

Primary Outcome Measure

Change in Brief Fatigue Inventory (BFI) Global Score [ Time Frame: Baseline to 8 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University Hospital Dialysis Medical Center (DMC)San AntonioTexas78229
Subrata Debnath, PhD
[email protected]
210-567-4700

Find similar trials in San Antonio, TX

By research site
University Hospital Dialysis Medical Center (DMC)· San Antonio, TX

Related Studies